F-1/A: Holdco Nuvo Group D.G Ltd. Announces Pre-Funded Warrant and Share Offering to Raise Up to $15 Million

Holdco Nuvo Group D.G Ltd. plans to offer up to $15 million in securities, including ordinary shares and warrants, to support its business and growth initiatives.

Summary

• Holdco Nuvo Group D.G Ltd. is planning to sell up to $15 million in securities.
• The offering includes ordinary shares, pre-funded warrants, Series A warrants, and Series B warrants.
• The securities will be offered directly to investors through Roth Capital Partners, LLC, acting as placement agent.
• The offering price is assumed to be $1.08 per share and accompanying warrants, or $1.079 per pre-funded warrant and accompanying warrants.
• The Series A Warrants will be immediately exercisable at $1.08 per share and expire in five years.
• The Series B Warrants will be immediately exercisable at $1.08 per share and expire in one year, with a cashless exercise option.
• Pre-funded warrants are offered to investors who would exceed a 4.99% ownership threshold.
• The offering is expected to terminate on August 14, 2024.
• Roth Capital Partners, LLC will receive a cash fee of 7.0% of the gross proceeds and reimbursement for expenses up to $250,000.
• The company intends to use the net proceeds to hire incremental sales and marketing personnel and focus resources on building the commercial aspects of our business, to continue to incur significant research and development expenses associated with moving our current product offering forward, including personnel related expenses and costs of conducting preclinical studies and clinical trials, to expand our accounting, finance and administrative staff and resources in connection with our transition to a public company, and for general corporate purposes.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is raising capital, which is generally positive, there are also risks and uncertainties associated with the offering, such as potential dilution and market volatility.

Positives

• The offering aims to raise capital for commercialization, research and development, and administrative expansion.
• The company has engaged Roth Capital Partners, LLC, a reputable placement agent, to assist with the offering.
• The Series A and B warrants provide potential upside for investors if the share price increases.

Negatives

• The offering is on a best efforts basis, and there is no guarantee that the company will raise the full $15 million.
• Investors will experience immediate and substantial dilution in the book value of their Ordinary Shares.
• There is no established trading market for the Pre-Funded Warrants or Series Warrants.
• The exercise price for Holdco Warrants is higher than the price of our Ordinary Shares, and, accordingly, the Holdco Warrants are more likely to expire worthless.

Risks

• The company may not raise sufficient proceeds to adequately fund its intended uses.
• The market price of the Ordinary Shares may be volatile.
• The company may not be able to effectively implement controls and procedures required by Section 404(a) of the Sarbanes-Oxley Act.
• The company may lose its foreign private issuer status, which would then require the company to comply with the Exchange Acts domestic reporting regime and cause the company to incur significant legal, accounting and other expenses.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about the companys business, the price of Ordinary Shares and Holdco trading volume could decline.

Future Outlook

The company intends to use the net proceeds from this offering to hire incremental sales and marketing personnel and focus resources on building the commercial aspects of our business, to continue to incur significant research and development expenses associated with moving our current product offering forward, including personnel related expenses and costs of conducting preclinical studies and clinical trials, to expand our accounting, finance and administrative staff and resources in connection with our transition to a public company, and for general corporate purposes.

Industry Context

The announcement reflects a company seeking capital to expand its operations in the competitive healthcare technology sector, particularly in women's health and remote pregnancy monitoring. This is a growing area, with increasing demand for accessible and convenient healthcare solutions.

Comparison to Industry Standards

• Comparable companies in the medical device and telehealth industries, such as Teladoc Health, Inc. and Dexcom, Inc., often utilize similar financing strategies to fund growth and innovation.
• The terms of the offering, including the warrant structure and placement agent fees, are generally consistent with industry standards for similar-sized companies.

Stakeholder Impact

• Shareholders will experience dilution.
• Employees may benefit from increased investment in the company.
• Customers may benefit from improved products and services.

Next Steps

• The company will proceed with the offering, subject to market conditions and regulatory approvals.
• The company will use the net proceeds to fund its business and growth initiatives.

Key Dates

Keywords

offering, warrants, ordinary shares, pre-funded warrants, securities, capital raise, placement agent, Holdco Nuvo Group